Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus
Lipella Pharmaceuticals Inc. (LIPO)
Company Research
Source: GlobeNewswire
All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week timepointPreparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration PITTSBURGH, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq : LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced positive final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in patients with symptomatic oral lichen planus (OLP). The study met its primary safety endpoint and achieved statistically significant improvements across all efficacy measures at the 4-week timepoint. These results support LP-10‘s potential to become the first FDA-approved therapy for OLP, a chronic
Show less
Read more
Impact Snapshot
Event Time:
LIPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIPO alerts
High impacting Lipella Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
LIPO
News
- Nasdaq to delist certain securities suspended from trading [Seeking Alpha]Seeking Alpha
- Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen PlanusPR Newswire
LIPO
Sec Filings
- 11/14/25 - Form 10-Q
- 10/21/25 - Form 8-K
- 10/9/25 - Form 8-K
- LIPO's page on the SEC website